Toremifene citrate 80 mg meets primary and key secondary endpoints in phase III clinical trial in advanced prostate cancer patients on androgen deprivation therapy

This article or press release has no online content. Please download the associated documents for more information.

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2021